Introduction and goal: Proinflammatory cytokines and prostaglandin E 2 (PGE 2 ) play an important role in the pathophysiology of osteolysis and implant loosening. The aim of this study was to evaluate the role of pharmacological agents in the inhibition of Interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-(TNF-) and PGE 2 in explants of interface membranes from failed total hip replacements (fTHR).
Introduction
Total hip replacement (THR) is the procedure of choice for patients over the age of 60 suffering from osteoarthritis (OA). Approximately 240 000 THR are performed every year in the US and Canada, and roughly 10% of these surgeries are revisions due to aseptic loosening. The pathophysiology of osteolysis in failed THR (fTHR) is related to a heavy macrophage response to implant debris at the bone-implant interface and the expression of several cytokines, namely tumor necrosis factor (TNF-), interleukin (IL)-1 and IL-6, prostaglandins (PG), metalloproteinases (MMP) and nitric oxide (NO). Moreover, most data in the literature have shown that the failure process is likely to have multifactorial causes, including prosthetic design, metal alloy debris, stress shielding, cement debris and more recently polyethylene wear debris [1] [2] [3] . Abundant wear debris and macrophages are found within membranes and synovial fluid surrounding loosened total hip prosthesis 4 . It has also been demonstrated that macrophages could differentiate directly into osteoclastic bone resorbing cells 5 , although the main pathway to macrophage differentiation into osteoclasts responsible for bone resorption in fTHR seems to be osteoblastdependent 6 . To date, there is no effective treatment other than a revision surgery for patients with fTHR due to aseptic loosening. Understanding the pathophysiology of osteolysis and the identification of the key modulators of the inflammatory cascade generated by wear debris in recent years has paved the way to potential pharmacological treatment of THR failure 7 . Although still experimental, these studies demonstrate that a new era in the prevention and treatment of osteolysis and THR failure is starting 8, 9 . Several drugs which inhibit prostaglandin synthesis have been examined in OA and wear debris-mediated osteolysis 10 . In OA, tiaprofenic acid showed modest activity 11 , diclofenac was inactive 12 , naproxen may affect some biochemical parameters 13 , and aspirin accelerated the development of severe OA 14 . In a wear debris model of osteolysis, indometacin increased TNF-expression by three-fold 7 , while pentofilin 15 and ethanercept 16 inhibited TNF-expression and the progression of experimental osteolysis.
Tenidap is an experimental antirheumatic drug of the oxindole class 17 . This drug has a dual action-inhibiting cyclooxygenases 18 and the production of proinflammatory cytokines such as IL-1, IL-6 and TNF-in human cell 19 , synovial membrane explants from rheumatic arthritis patients 20, 21 , and on a dog model of OA 12 . Tenidap has been demonstrated to be an effective drug in the treatment of rheumatoid arthritis [22] [23] [24] . In vivo, this drug was shown to be capable of reducing, in arthritic patients, several biological markers of inflammation and IL-6 19, 21, 22 . The effect of tenidap on CRP and SAA proteins is likely related to the suppression of cytokine synthesis 19, 21, 25 . The relevance of tenidap's action as a cytokine modulating agent vis-à -vis osteolysis is most interesting as several reports have indicated that, at the clinical stage of the disease, variable degrees of inflammation are present 26, 27 and that interface membranes in failed THR synthesize an increased amount of IL-1 , IL-6, TNF-and PGE 2 28 . The aim of this study was to evaluate the efficacy of simultaneous inhibition of cytokines and PGE 2 in response to tenidap, a potent cytokine modulator, in explants of interface membranes from failed total hip arthroplasties, and to compare their effect with diclofenac, a currently used non-steroidal antiinflammatory drug (NSAID).
Material and methods

PATIENT CHARACTERISTICS
Interface membrane specimens were obtained from the proximal femur at Gruen zones I and VII 29 at the time of surgery from 20 patients undergoing revision procedures for clinical failure of total hip arthroplasty ( Table I ). All patients had a failed hybrid THR with a metal on ultra high molecular weight polyethylene (UHMWPE) bearing in order to minimize individual variability due to different wear debris.
The indication for a revision included pain and evidence of loosening. The presence of radiolucent lines at the bone interface and the migration of a component according to radiographic data confirmed loosening. The radiographs from the loose implants with osteolysis contained one or more areas showing ballooning and radiolucent zones with scalloped edges adjacent to the cement mantle or bone.
Twelve patients were men and eight were women. They all had a diagnosis of OA at the time of their primary THR. The mean age (61.7±5.6 years, 65.4±5.6 years old, mean±S.E.M., respectively) and the time to revision (57.0± 12.9 months, 49.2±11.5 months, mean±S.E.M., respectively) for both men and women were similar. In all patients, both clinical and radiographic appearances were of aseptic prosthetic failure. Infection cases were excluded by clinical history and microbiology confirmation.
This study was approved by the Institutional Research Committee/Institutional Ethics Committee of the Centre hospitalier de l'Université de Montré al. EXPLANT 
CULTURE
Each interface membrane was aseptically dissected from underlying bone and rinsed in cold saline solution. Tissue samples were sectioned into small fragments of 4-5 mm in diameter. Explants weighing roughly 250 mg were processed, randomly divided, and cultured in duplicate in 12-well plates (Costar, Cambridge, MA, U.S.A.) with 4 ml Dulbecco modified Eagle's medium (DMEM, GIBCOLife Technologies, Burlington, ON, Canada), containing penicillin and streptomycin sulfate (100 U/ml and 100 g/ ml, respectively; GIBCO). No serum was present in the culture medium 20 . Pilot studies were performed at 24 h, 48 h, and 72 h incubation to determine the ideal experimental conditions. Cultures were incubated at 37°C for 72 h in a humidified 5% CO 2 /95% air mixture in the absence or presence of tenidap ([Z]-5-chloro-2, 3 dihydro-3-[hydroxy-2-thienyl methylene]-oxo-1H-indole-1-carboxamide, sodium salt) (Pfizer Central Research, Groton, CT, U.S.A.) at final concentrations of 5, 20 or 50 g/ml or diclofenac sodium (Sigma-Aldrich, St Louis, MO, U.S.A.) at final concentration of 125 g/l. The ideal therapeutic plasma level in patients is 20 g/ml for tenidap 30 . The concentration of diclofenac used in the present in vitro experiments was similar to therapeutic levels found in plasma and synovial fluid after oral administrations of the drug in humans 31 . Tenidap and diclofenac were dissolved in ethanol and further diluted to achieve the required final concentrations. In each incubation well, the ethanol concentration did not exceed 0.1% (V/V). For each specimen, there were appropriate controls for ethanol. At the end of the incubation period, explants were weighed to normalize cytokine and PGE 2 levels as per gram of tissue wet weight (gww) 32 , and the culture medium was collected and stored at −80°C until further use 20 . All patients had a diagnosis of hip osteoarthritis at the time of the primary total hip replacement. Only failed hybrid THR with metal on UHMWPE bearings were included in the study to standardize patient selection.
*fTHR: Failed total hip replacement.
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The levels of IL-1 , IL-6 and TNF-were determined in the culture medium of membrane explants by a capture antibody in a sandwich enzyme-linked immunosorbent assay (ELISA Capture) 33 . The IL-1 , IL-6 Kit and TNF-(high sensitivity) were obtained from R&D Systems, (Minneapolis, MN, U.S.A.). Each ELISA was performed according to the manufacturer's specification. Sensitivity to the culture medium was 0.3 pg/ml for IL-1 , 3 pg/ml for IL-6 and 4.4 pg/ml for TNF-. PGE 2 DETERMINATION PGE 2 was measured in the explant culture supernatants using the PGE 2 Immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, U.S.A.). This assay is based on the competition between PGE 2 and a PGE 2 -acetylcholinesterase conjugate (PGE 2 tracer) for a limited amount of PGE 2 monoclonal antibody 33 . All reactions were measured on a micro-ELISA Vmax photometer (Molecular Devices Corp., Menlo Park, CA, USA). Data were expressed in ng/g tissue wet weight (ng/gww, IL-6 or PGE 2 ) or pg/g tissue wet weight (pg/gww, IL-1 or TNF-) 32 .
STATISTICAL ANALYSIS
Twenty patients were included in this study (N=20). Each membrane explanted from a given patient was tested for every experimental condition. To avoid discrepancies in cytokine and PGE 2 levels when working with explants, two samples of the same membrane were cultured for every experimental condition and the mean result was included in the statistical analysis as the only corresponding data for a given patient. Therefore, our statistical analysis was based on 20 separate results for each variable (N=20). Mean values and standard errors of the mean were calculated, and statistical analysis was done using the Mann-Whitney U-test. P values equal or less than 0.05 were considered significant.
Results
CYTOKINE AND PGE 2 SYNTHESIS IN EXPLANTS
Preliminary experiments were carried out using revision interface membranes explants, and the levels of inflammatory mediators were measured. Cytokine levels over various lengths of incubation time were also measured, and the optimal incubation time was found to be 72 h.
At first, we examined the level of cytokine and PGE 2 synthesis in membrane specimens of loosened implant with osteolysis. The membrane explants produced IL-1 , IL-6, TNF-and PGE 2 . Cytokine and PGE 2 production varied considerably between patient samples. The secretion of IL-1 (194.72±52.47 pg/gw, mean±S.E.M.) and TNF-(4.04±0.70 pg/gww, mean±S.E.M.) were in the picogram range, while the levels of IL-6 (183.34±110.04 ng/ gww, mean±S.E.M.) and PGE 2 (791.53±310.99 ng/gww, mean±S.E.M.) were in the nanogram range.
EFFECTS OF DRUGS ON CYTOKINES AND PGE 2
IL-1 was detected on all the specimens used. As shown in Fig. 1 , a statistically significant decrease in the IL-1 synthesis was found at two tenidap concentrations tested; with inhibition of 71.3% (P<0.05) at a therapeutic (20 g/ ml) concentration and 79.3% (P<0.02) at a supratherapeutic concentration (50 g/ml). Although the level of IL-1 in the tenidap-treated specimens was reduced by 51.0% at a concentration of 5 g/ml, these results are not statistically different from the untreated (control) specimens. Diclofenac (125 g/l) had no significant effect on the inhibition of IL-1 synthesis.
The interface membrane explants produced a very high level of IL-6 compared with the two other cytokines studied (IL-1 and TNF-). Our results showed that tenidap, at a sub-therapeutic concentration (5 g/ml), reduced IL-6 production by 77.5%, but there was no significant difference with the control group (Fig. 2) . The reduction was statistically significant at 90.4% (P<0.005) and 96.0% (P<0.05) at 20 g/ml and 50 g/ml, respectively. The level of IL-6 in diclofenac-treated explants was similar to that in the control.
We could only detect TNF-levels in the specimens with a high sensitivity ELISA kit. The levels of TNF-protein were relatively small compared with the other two cytokines (IL-1 and IL-6) tested. The level of TNF-in the specimens treated with 5 g/ml tenidap was slightly higher than the control. In the presence of tenidap, a reduction of synthesis of 66.9% (P<0.05) and 77.4% was noted at concentration of 20 g/ml and 50 g/ml. There was no statistically significant difference between 20 g/ml and the control. The level of TNF-in the diclofenac-treated explants (125 g/l) was not changed compared to the untreated control (Fig. 3) .
A significant level of PGE 2 was present in all interface membranes. Tenidap had a marked and significant suppressive effect at all three concentrations used (5 g/ml, 20 mg/ml and 50 g/ml, respectively) on PGE 2 synthesis. Fig. 1 . Levels of interleukin-1 (IL-1 ) in the culture medium of interface membrane explants. Failed total hip replacement (fTHR) interface membranes were retrieved at the time of revision surgery (N=20) and explants were done as described in Material and methods. The levels of IL-1 were determined in the culture medium using ELISA capture and expressed as picograms of IL-1 per gram of tissue wet weight (pg/Gww). Explants from fTHR treated with tenidap had a significant decrease in IL-1 levels compared to untreated controls. There was no significant decrease in IL-1 levels in the diclofenac-treated group when compared to untreated controls. Values are expressed as the mean±S.E.M. and statistical analysis was done by two-tailed Mann-Whitney U-test.
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Inhibition higher than 90% (P<0.0001) was observed for all tissues examined. Similarly, diclofenac significantly inhibited (P<0.0001) PGE 2 production at the interface membranes by 95% using therapeutic concentrations of the drug (125 g/l) (Fig. 4) .
Discussion
This study shows that tissue retrieved from fTHR synthesized significant levels of proinflammatory cytokines and PG. Indeed, high levels of PGE 2 , IL-1 , IL-6 and TNFwere synthesized by the tissue surrounding loose implant with osteolysis. This phenomenon suggests that numerous cytokines and other proinflammatory mediators are produced by bone and interface membranes of loosened prosthesis and that specific cytokines, namely IL-1 , IL-6 and TNF-are associated with osteolysis 34 . We have run preliminary assays at 24 h, 48 h and 72 h in a pilot study to address the question whether tissue extracts should have been used instead of culture medium after 72 h incubation in order to detect fine differences in our in vitro system. TNF-was not detectable in significant levels prior to 72 h incubation in the culture medium and, yet, a TNF-highsensitivity kit from R & D Systems (Minneapolis, U.S.A.) had to be used. Moreover, IL-1 levels were also at the picogram range at 72 h. Since TNF-is considered to be the single most important cytokine implicated in weardebris induced osteolysis [35] [36] [37] , it seems logical that the other cytokines and PGE 2 should also be measured at 72 h. Our group has already successfully measured cytokine levels in the culture medium of RA synovial membranes explants at 72 h incubation with consistent results 20 . This corroborates the numerous studies that suggest the excess synthesis and secretion of proinflammatory cytokines from macrophages stimulated with wear particles play a major role in the pathophysiology of osteolysis and loosening process 38, 39 . Cytokines exert their action by binding to specific cell membrane receptors and transducing intracellular signals. IL-1 and TNF-are very potent inducers of proteolytic enzymes, such as MMP, which can destroy the interface tissues and remove osteoid, thereby promoting osteolysis and providing a surface for osteoclastic bone resorption 2, 4, 28 . IL-6 is also implicated in the modulation of bone resorption by the osteoclasts 40 . The level of IL-6 was found in synovial fluid to be 10 times higher in revision total joint arthroplasties with osteolysis than those without osteolysis 2 . There is higher cytokine expression in tissues surrounding cemented prostheses when compared to prostheses without cement 28 . The excess synthesis of PGE 2 by interface membranes at the site of aseptic loosening is also one of the factors contributing to osteolysis and the loosening process 34,41-43 . Fig. 2 . Levels of interleukin-6 (IL-6) in the culture medium of interface membrane explants. Failed total hip replacement (fTHR) interface membranes were retrieved at the time of revision surgery (N=20) and explants were done as described in Material and methods. The levels of IL-6 were determined in the culture medium using ELISA Capture and expressed as nanograms of IL-6 per gram of tissue wet weight (ng/Gww). There was no significant decrease in IL-6 levels in the diclofenac-treated group when compared to untreated controls. Values are expressed as the mean±S.E.M. and statistical analysis was done by two-tailed MannWhitney U-test. Fig. 3 . Levels of tumor necrosis factor-(TNF-) in the culture medium of interface membrane explants. Failed total hip replacement (fTHR) interface membranes were retrieved at the time of revision surgery (N=20) and explants were done as described in Material and methods. The levels of TNF-were determined in the culture medium using ELISA Capture (high sensitivity) and expressed as picograms of TNF-per gram of tissue wet weight (pg/Gww Our results demonstrate that tenidap significantly inhibited the expression of several cytokines from 67% up to 90% in therapeutic concentrations. The inhibition of TNFby tenidap was between 66.9% and 77.4% (P<0.05) depending on the concentration used and that of IL-1 was between 71% (P<0.05) and 79% (P<0.02). Moreover, the level of IL-6 production was reduced by 90.4% (P<0.005) at the lower tenidap concentration and by 96.0% (P<0.05) at the higher concentrations. Tenidap also had a marked suppressive effect of over 90% (P<0.0001) on PGE 2 synthesis at all three concentrations used.
Tenidap, a drug from the chemical class of the oxindoles, has been shown to modulate cytokine (IL-1 , IL-6 and TNF-) production in synovial membrane of RA patients 20 . Tenidap also reduced in vivo IL-1 activity in synovial fluid as well as the activity and/or expression of MMP in cartilage in a canine experimental model 44 . Tenidap was chosen for this study because of its very potent cytokine synthesis inhibition both in vitro 20 and in vivo 44 . On the other hand, diclofenac, a NSAID belonging to the arylakanoic groups of phenylacetic acid, significantly inhibited the synthesis of PGE 2 , a major factor associated with the pathophysiology and symptoms of osteolysis and implant loosening. However, no effects were observed on the synthesis of cytokines, which are known to be very important modulators of osteolysis in periprosthetic tissues.
Much of the work to find a pharmacological treatment for aseptic loosening has focused on bisphosphonates and TNF-antagonists 15, 16, 45, 46 . The potential of TNF-antagonists has already been demonstrated in an animal model in osteolysis 16 . Thus, the reduction in TNF-production by tenidap should have a similar effect on osteolysis prevention. Also, the production of IL-6 and PGE 2 by particleactivated osteoblasts is thought to negatively influence the gene expression of procollagen and favor recruitment of osteoclastic cells 34, 41 . The inhibition of PGE 2 observed in this study was not associated to a concomitant decrease in cytokine levels in the diclofenac group. PGE 2 is directly related to IL-6 expression 47 . Significantly suppressing PGE 2 by 95% from 0 h to 72 h using either drug has most likely downplayed the increased levels of IL-6 found in the culture medium. Nevertheless, a significant inhibition of PGE 2 should have also theoretically decreased IL-6 levels in the diclofenac group, which was not the case. Contrary to diclofenac, tenidap also seemed to have a direct inhibitory effect on IL-1, IL-6 and TNF-, which explains its efficacy even at 72 h of incubation compared to PGE 2 inhibition alone. The reduction of IL-6 and PGE 2 secretion by tenidap could help restore the normal balance between bone formation and bone resorption in implant failure.
The interaction between osteoblasts, macrophages and osteoclasts in aseptic loosening of orthopedic implants is underestimated in the literature. However, accumulating evidence suggests that the osteoblasts play a central role in recruiting and activating cells responsible for bone destruction 1, 3, 41, 42 . Modulation not only of proinflammatory cytokines but also PGE 2 synthesis by pharmacological agents is of prime importance in avoiding orthopedic implant loosening and osteolysis 37, 43, 48 . Our findings suggest a possible role for multiple cytokine inhibition in the treatment/prevention of patients suffering from aseptic loosening. To our knowledge, this is the first time that simultaneous inhibition of multiple cytokines and PG in the interface membrane by a pharmacological agent has been reported. Further studies in vivo are necessary to evaluate the simultaneous inhibition of these proinflammatory cytokines in the pathophysiology of implant loosening, as well as its correlation to osteoblastic activity 40 . These findings pinpoint specific targets for potential pharmacological prevention of failed total joint arthroplasties and provide alternatives to surgical treatment.
